This site is intended for health professionals only
Wednesday 19 December 2018
Share |

Topic: Research

November 15, 2018
Matt Hancock made the comments during a five-hour cabinet meeting discussing the Brexit deal negotiated with the EU by Prime Minister Theresa May, according to The Times

The UK's health minister told cabinet members he could not guarantee there would be no deaths if Britain exits the European Union (EU) without a deal, The Times newspaper has reported.
 
Matt Hancock made the comments during a five-hour cabinet meeting discussing the Brexit deal negotiated with the EU by Prime Minister Theresa May, according to the newspaper.
 

November 7, 2018
Olarpip could provide effective treatment for brain tumours, charity reveals

An ovarian cancer drug could be an effective treatment for a difficult-to-treat type of brain tumour, research by a cancer charity has revealed.
 
Olaparib could leak through the blood brain barrier to treat glioblastoma – a condition which many other drugs have failed to treat – according to a study presented at the National Cancer Research Institute’s (NCRI) Cancer Conference in Liverpool on Monday (5 November).
 

November 7, 2018
Olarpip could provide effective treatment for brain tumours, charity reveals

An ovarian cancer drug could be an effective treatment for a difficult-to-treat type of brain tumour, research by a cancer charity has revealed.
 
Olaparib could leak through the blood brain barrier to treat glioblastoma – a condition which many other drugs have failed to treat – according to a study presented at the National Cancer Research Institute’s (NCRI) Cancer Conference in Liverpool on Monday (5 November).
 

October 31, 2018
Researchers make breakthrough on sexually transmitted bacterium

Scientists have discovered the mechanism by which a bacterium adheres to human cells, which is essential for the onset of bacterial infection and disease development.
 
The researchers from the Molecular Biology Institute of Barcelona (IBMB) and the Institute of Biotechnology and Biomedicine (IBB) studied the bacterium mycoplasma genitalium (Mgen) and how it adheres to human cells.
 
They found the mechanism by which it interacts with cells, which the researchers hope will lead to new treatments to fight the infection.
 

October 31, 2018
Scientists discover source for counteracting drug resistance in tumour cells

Researchers have discovered a way of re-sensitising tumour cells that are resistant to cancer drugs.
 
The study, conducted by biologists at the University of California in San Diego, found that a human gene known as Schlafen 11 controls the sensitivity of tumour cells to DNA-damaging agents, which make up most of the widely used cancer drugs.
 

October 31, 2018
Scientists discover source for counteracting drug resistance in tumour cells

Researchers have discovered a way of re-sensitising tumour cells that are resistant to cancer drugs.
 
The study, conducted by biologists at the University of California in San Diego, found that a human gene known as Schlafen 11 controls the sensitivity of tumour cells to DNA-damaging agents, which make up most of the widely used cancer drugs.
 

October 17, 2018
ImraldiTM approved in the European Union for 13 of the same complex autoimmune conditions as its reference product is now available through the NHS

ImraldiTM is approved in the European Union (EU) for 13 of the same complex autoimmune conditions as its reference product and is now available in the UK via the NHS.
 
Imraldi is approved in Europe for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis; enthesitis-related arthritis), axial spondyloarthritis (ankylosing spondylitis (AS) and axial spondyloarthritis with radiographic evidence of AS).
 

September 26, 2018
My role as a clinical education research pharmacist

Clinical education research pharmacist Michael Lloyd shares his pharmacy journey
 
Undergraduate experiences developed an interest in quantitative research, with my early career seeing involvement in many audits and quality improvement projects. I later completed a postgraduate Master’s degree that illuminated the world of qualitative methodologies and I was hooked!
 

September 26, 2018
My role as a clinical education research pharmacist

Clinical education research pharmacist Michael Lloyd shares his pharmacy journey
 
Undergraduate experiences developed an interest in quantitative research, with my early career seeing involvement in many audits and quality improvement projects. I later completed a postgraduate Master’s degree that illuminated the world of qualitative methodologies and I was hooked!
 

June 27, 2018
Oral Semaglutide demonstrates significant reduction in blood sugar versus placebo in trial

A once-daily tablet could reduce blood sugar in adults with type 2 diabetes, a study has shown.
 
Oral semaglutide, an investigational GLP-1 analogue from global healthcare company Novo Nordisk,achieved “significant reductions in blood sugar versus placebo in adults with type 2 diabetes”, according to the PIONEER 1 phase 3a trial.
 
The trial evaluated the efficacy and safety of 3, 7 and 14 mg oral semaglutide compared with placebo as monotherapy over 26 weeks in adults with type 2 diabetes. [1] 
 

June 25, 2018
Stephanie Annett has a PhD in experimental therapeutics, is a researcher for novel immunotherapies and a lecturer of pharmacology at the Royal College of Surgeons Ireland and locums in community pharmacy

Stephanie Annett has a PhD in experimental therapeutics, is a researcher for novel immunotherapies and a lecturer of pharmacology at the Royal College of Surgeons Ireland and locums in community pharmacy.
 
She talks to Léa Legraien about her passion for research and pharmacy and her success.
 
 
Q Why did you become a pharmacist?
 
I was always interested in science, which I had chosen at A-level.
 

June 25, 2018
Stephanie Annett has a PhD in experimental therapeutics, is a researcher for novel immunotherapies and a lecturer of pharmacology at the Royal College of Surgeons Ireland and locums in community pharmacy

Stephanie Annett has a PhD in experimental therapeutics, is a researcher for novel immunotherapies and a lecturer of pharmacology at the Royal College of Surgeons Ireland and locums in community pharmacy.
 
She talks to Léa Legraien about her passion for research and pharmacy and her success.
 
 
Q Why did you become a pharmacist?
 
I was always interested in science, which I had chosen at A-level.
 

June 21, 2018
Targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors

A targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers have found.
 
EZH2 is elevated in immune T cells in patients after treatment with ipilimumab, a team at the University of Texas MD Anderson Cancer Center showed. The drug unleashes an immune response by blocking the activity of CTLA-4 on T cells – white blood cells that serve as the ‘targeted warriors’ of the adaptive immune system.
 

June 20, 2018
Idorsia launches PRECISION – Phase 3 study with aprocitentan for resistant hypertension management in adults

Swiss biopharmaceuticals business Idorsia has announced that the first patient has been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for managing resistant hypertension in adults [June 20 2018].
 

May 3, 2018
Leading cancer charities launch awards to help advance understanding of the disease and develop new treatments to improve survival

Leading cancer charities have established a multi million pound fund to improve the understanding and treatment of brain tumours.

 

The Cancer Research UK Brain Tumour Awards was launched this month [1 May] by Cancer Research UK in partnership with The Brain Tumour Charity to help advance understanding about the biology of the disease and the challenges translating discoveries into treatments.

 

April 12, 2018
Gene discovery could lead to future individualised therapy in myeloma, researchers find

Researchers have increased the understanding of the complex genetics behind an incurable blood cancer.

 

The Institute of Cancer Research, London, has conducted a study which has revealed 40 genes involved in the development of myeloma, enhancing the knowledge about the complex genetics associated with this condition.

 

April 6, 2018
<p>UK Biobank has announced a major initiative to sequence the full genomes of 50,000 UK Biobank volunteer participants</p>

Funded by a £30M grant from the Medical Research Council (MRC), sequencing of the whole genome will be undertaken during 2018 and 2019 by the Wellcome Sanger Institute, which is based in Cambridge.

 

February 9, 2018
Pharmacists have a vital role in early identification and reconciliation of medications in PD patients and this has the potential to prevent deterioration and prevent further morbidity in this patient profile.

Abstract

Introduction Parkinson's disease (PD) is a high-risk chronic condition putting patients at risk of a number of potential complications if not managed appropriately. Emergency departments (EDs) are often ill-equipped to reconcile and continue vital medications for PD, and dramatic deterioration in symptoms and increased morbidity may occur as a result. The role of pharmacists in early reconciliation in this high-risk patient group is not fully explored in the current literature. 

 

February 8, 2018
Doctors have developed a new five-minute procedure to scan the blood vessels which offers hope for claustrophobic patients unable to tolerate the conventional longer test

Magnetic resonance angiography (MRA) is a magnetic resonance imaging (MRI) exam that takes pictures of the blood vessels. Physicians use the images to diagnose diseases of the blood vessels, such as aneurysms or blockages.
 

December 12, 2017
Globally, 694,000 people die from bowel cancer and 1.4 million people are diagnosed every year

Almost 332,000 people living in the UK will needlessly lose their lives to bowel cancer – a preventable, treatable and curable disease – between now and 2035 unless urgent action is taken to fill critical research gaps identified in a Bowel Cancer UK report ‘Finding the Key to the Cures: a plan to end bowel cancer by 2050’ launched today. If ignored, the scale of the issue will only grow larger.


The research has been published in the leading international academic journal, Gut.

December 1, 2017
Combining two different immunotherapy treatments could dramatically improve lymphoma survival, according to a Cancer Research UK funded study published in Cancer Cell

Researchers from the University of Southampton have tested different combinations of antibodies in the lab to see how they interact with each other and what effect this has on how the immune system fights cancer.


They found one combination – anti-CD27 and anti-CD20 – greatly increased life expectancy in mice with cancer. While most of the mice given just one of the antibodies died within 80 days, nearly all mice given both antibodies survived beyond 100 days.

May 18, 2016
Efficacy and tolerability were maintained in patients who switched from reference infliximab to biosimilar infliximab over the duration of the study with the results showing comparability to those patients who continued treatment on biosimilar infliximab

Long term data from the pivotal phase III PLANETRA study over 102 weeks demonstrating the clinical efficacy and safety profile of biosimilar infliximab in RA patients, has been published in Annals of the Rheumatic Diseases this month.1

May 17, 2016
A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential of combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin

A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential of combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin. This collaboration strengthens A1M Pharma’s position in the use of A1M for the treatment of life-threatening diseases with therapies that are based on naturally occurring substances.
 

May 17, 2016
A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential of combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin

A1M Pharma has initiated a research collaboration with global biotherapeutics company CSL Behring to investigate the potential of combining Alpha 1 Microglobulin (A1M) with proteins extracted from the fractionation of human plasma such as hemopexin and haptoglobin. This collaboration strengthens A1M Pharma’s position in the use of A1M for the treatment of life-threatening diseases with therapies that are based on naturally occurring substances.
 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine